ReviewPublic health genomics2009
A health services research agenda for cellular, molecular and genomic technologies in cancer care.
Review in Public health genomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop.Genetics in medicine : official journal of the American College of Medical Genetics · 2009Guideline
- Examining access to care in clinical genomic research and medicine: Experiences from the CSER Consortium.Journal of clinical and translational science · 2021Article
- Capturing the clinical utility of genomic testing: medical recommendations following pediatric microarray.European journal of human genetics : EJHG · 2015Article
- Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.European journal of human genetics : EJHG · 2014Article
- Rethinking our public health genetics research paradigm.American journal of public health · 2013Article
- Barriers to the use of personalized medicine in breast cancer.Journal of oncology practice · 2012Article
- A population approach to precision medicine.American journal of preventive medicine · 2012Article
- Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting.Journal of cancer epidemiology · 2012Article
- Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Review
- Translational research in cancer genetics: the road less traveled.Public health genomics · 2011Article
- Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing.BMC health services research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundIn recent decades, extensive resources have been invested to develop cellular, molecular and genomic technologies with clinical applications that span the continuum of cancer care.
methodsIn December 2006, the National Cancer Institute sponsored the first workshop to uniquely examine the state of health services research on cancer-related cellular, molecular and genomic technologies and identify challenges and priorities for expanding the evidence base on their effectiveness in routine care.
resultsThis article summarizes the workshop outcomes, which included development of a comprehensive research agenda that incorporates health and safety endpoints, utilization patterns, patient and provider preferences, quality of care and access, disparities, economics and decision modeling, trends in cancer outcomes, and health-related quality of life among target populations.
conclusionsUltimately, the successful adoption of useful technologies will depend on understanding and influencing the patient, provider, health care system and societal factors that contribute to their uptake and effectiveness in 'real-world' settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.